Bonum Therapeutics
Seattle, US · Founded 2021 · Delaware corporation · 20 employees on LinkedIn · 6 known investors
Find your way into Bonum Therapeutics
937 people in our graph share verified history with the Bonum Therapeutics team — schools, employers, funds. One of them is your warm intro.
Mike Volpiunlockedknows Neela Patel · together at Stanford University (overlapped)
×7knows the team · via Stanford University
knows the team · via Bonum Therapeutics
×2knows the team · via Massachusetts Institute of Technology
knows the team · via UCLA
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.
Founders & leadership
Bonum Therapeutics was founded in 2021 by John Mulligan.
JM
John MulliganinFounder and CEOHe has held scientific and leadership roles at multiple drug discovery and synthetic biology companies, including Darwin Molecular (where he contributed to target identification using human genetics and an osteoporosis drug target that led to Amgen's approved Evenity), Glycostasis (where he developed glucose-responsive insulin technology), and Good Therapeutics (where he served as CEO and invented core technology before its acquisition by Roche in 2022).
NP
Neela PatelinCBOExecutive Officer of Bonum Therapeutics, which develops antibody-controlled protein therapeutics for cancer and other diseases. Patel has experience in business development, including collaborations and licensing, and a track record in drug discovery and strategic planning.
DH
Diane HollenbaughinCSO
Board
SB
MS
JM
John McKearnin𝕏Board directorSenior Advisor at RiverVest Venture Partners, focused on early-stage biotech
KH
NW
Nicholas WalrodinBoard of Directors2022–2026Managing Partner at American Century Private Investments
MM
Mitchell MutzinBoard director
GA
SB
Samuel BlackmanBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$73.1M disclosed across 3 rounds · 2021–2026
▶$26.9MraisedApr 2026 · 8 investors · BiotechnologyRule 506(b)
▶$26.9MraisedApr 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Samuel BjorkDirector
- Monique SchiersingDirector
- Neela PatelExecutive Officer
- John McKearnDirector
- Diane HollenbaughExecutive Officer
- Samuel BlackmanDirector
- John MulliganExecutive Officer, Director, Promoter
- Karl HandelsmanDirector
- Nicholas WalrodDirector
- Mitchell MutzDirector
- Gaurav AggarwalDirector
- Offering amount
- $32.3M
- Amount sold
- $26.9M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$45MraisedNov 2022 · 10 investors · BiotechnologyRule 506(b)
▶$45MraisedNov 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karl HandelsmanDirector
- John MulliganExecutive Officer, Director, Promoter
- Nicholas WalrodDirector
- Monique SchiersingDirector
- John McKearnDirector
- Samuel BjorkDirector
- Diane HollenbaughExecutive Officer
- Neela PatelExecutive Officer
- Mitchell MutzDirector
- Offering amount
- $93M
- Amount sold
- $45M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.2MraisedDec 2021 · 5 investors · BiotechnologyRule 506(b)
▶$1.2MraisedDec 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karl HandelsmanDirector
- Diane HollenbaughExecutive Officer
- Neela PatelExecutive Officer
- John McKearnDirector
- Monique SchiersingDirector
- Nicholas WalrodDirector
- John MulliganExecutive Officer, Director, Promoter
- Offering amount
- $3.6M
- Amount sold
- $1.2M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Bonum Therapeutics went on to found or lead other companies.
Competitors · 1
by search overlap
Companies competing with Bonum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Bonum Therapeutics do?
- Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity. Its pipeline focuses on antibody-controlled cytokines for cancer treatment, with potential applications in autoimmune disease, metabolic disorders, and pain management.
- Who founded Bonum Therapeutics?
- Bonum Therapeutics was founded by John Mulligan in 2021.
- Who are Bonum Therapeutics's investors?
- Bonum Therapeutics's investors include RiverVest Venture Partners, Roche Venture Fund, Vivo Capital, 3x5 Partners, Codon Capital, Digitalis Ventures.
- How much funding has Bonum Therapeutics raised?
- Bonum Therapeutics has disclosed $73.1M raised across 3 rounds.
- Where is Bonum Therapeutics headquartered?
- Bonum Therapeutics is headquartered in Seattle, US.